The US Food and Drug Administration has approved the BTK inhibitor ibrutinib for CLL treatment, and acalabrutinib has achieved an overall response rate of 95% in the treatment of relapsed CLL [54]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.